West Pharmaceutical Services, Inc.
WSTNYSEHealthcare● Active
$318.75
+$4.25(+1.35%)
Market Cap$22.5B
P/E Ratio—
52W High$330.88
52W Low$206.8
West Pharmaceutical Services, Inc. (WST) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · WST · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B |
| Cost of Revenue | $1.97B | $1.89B | $1.82B | $1.75B | $1.66B |
| Gross Profit | $1.10B | $1.00B | $1.13B | $1.14B | $1.17B |
| Gross Margin %(computed) | 35.89% | 34.65% | 38.38% | 39.47% | 41.45% |
| Operating Expenses | |||||
| R&D Expenses | $0.07B | $0.07B | $0.07B | $0.06B | $0.05B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.49B | $0.41B | $0.42B | $0.38B | $0.41B |
| Operating Income | $0.62B | $0.59B | $0.71B | $0.76B | $0.76B |
| Operating Margin %(computed) | 20.09% | 20.56% | 24.09% | 26.46% | 26.80% |
| Interest Income | $0.02B | $0.02B | $0.03B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.01B | $0.01B | $0.01B |
| Income Before Tax | $0.62B | $0.60B | $0.72B | $0.70B | $0.77B |
| Income Tax Expense | $0.12B | $0.11B | $0.12B | $0.11B | $0.11B |
| Net Income | $0.49B | $0.49B | $0.59B | $0.59B | $0.66B |
| Net Margin %(computed) | 16.06% | 17.03% | 20.11% | 20.30% | 23.38% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $6.83 | $6.75 | $7.99 | $7.88 | $8.90 |
| Wtd Avg Shares | 0.07B | 0.07B | 0.07B | 0.07B | 0.07B |
| EBITDA | $0.72B | $0.74B | $0.84B | $0.81B | $0.88B |
| EBITDA Margin %(computed) | 23.54% | 25.71% | 28.60% | 28.01% | 31.08% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more West Pharmaceutical Services, Inc. data
About West Pharmaceutical Services, Inc. (WST) Income Statement
West Pharmaceutical Services, Inc. (WST) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, WST reported revenue of $3.07B, gross profit of $1.10B (gross margin 35.89%), and net income of $0.49B — a net profit margin of 16.06%.
Frequently asked questions
WST · 4 questionsWest Pharmaceutical Services, Inc. (WST) reported revenue of $3.07B for 2025, up 6.3% year-over-year.
WST revenueWST salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08